Compounds which inhibit members of the histone deacetylase family of enzymes and their use in the treatment of cell proliferative diseases
Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent ═C— or ═N—; W is a divalent radical —CH═CH— or CH 2 CH 2 —; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L 1 , and X 1 are as defined in the claims.
1. A compound which is cyclopentyl (2 S )-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate, of formula:
or a pharmaceutically acceptable salt or N-oxide thereof.
2. A pharmaceutical composition comprising a compound according to claim 1 , together with a pharmaceutically acceptable carrier.
3. A pharmaceutical composition as claimed in claim 2 which is adapted for topical administration.
4. A The compound cyclopentyl (2 S )-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate, of formula;
5. A pharmaceutical composition comprising a compound as claimed in claim 4 , together with a pharmaceutically acceptable carrier.
6. A pharmaceutical composition as claimed in claim 5 which is adapted for topical administration.
7. The compound (2 S )-Cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetic acid.
8. A pharmaceutical composition comprising a compound according to claim 1 , wherein said composition is adapted for oral administration.
9. A pharmaceutical composition according to claim 8 , wherein the composition is present in the form of a tablet or capsule.
10. A pharmaceutical composition according to claim 8 , wherein said composition is present in the form of an oral liquid preparation.
11. A pharmaceutical composition comprising the compound according to claim 4 , wherein said composition is adapted for oral administration.
12. A pharmaceutical composition according to claim 11 , wherein the composition is present in the form of a tablet or capsule.
13. A pharmaceutical composition according to claim 11 , wherein said composition is present in the form of an oral liquid preparation.